Guggenheim Has Lowered Expectations for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) had its price objective decreased by equities researchers at Guggenheim from $60.00 to $59.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim‘s target price points to a potential upside of 157.42% from the company’s current price.

Several other equities research analysts have also commented on the stock. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. Wall Street Zen lowered shares of Damora Therapeutics, Inc. Common Stock from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of “Buy” and an average price target of $46.38.

Damora Therapeutics, Inc. Common Stock Stock Up 4.8%

Shares of Damora Therapeutics, Inc. Common Stock stock traded up $1.06 on Friday, reaching $22.92. The company’s stock had a trading volume of 64,768 shares, compared to its average volume of 431,905. The company has a market capitalization of $1.41 billion, a P/E ratio of -6.80 and a beta of 1.52. Damora Therapeutics, Inc. Common Stock has a 52-week low of $4.95 and a 52-week high of $38.33. The stock has a 50-day moving average price of $22.86 and a 200-day moving average price of $25.72.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.12. Sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of the firm’s stock in a transaction on Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds and other institutional investors have recently made changes to their positions in DMRA. Squarepoint Ops LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth $303,000. Arizona State Retirement System purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. Seven Fleet Capital Management LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $42,146,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.